Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
MENS Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS
Total Equity · Q4 FY2025 · quarter ended Dec 2025
Total equity remains negative
Q4 FY2025 total equity was -$24.91M, compared with -$36.52M a year earlier.
Context
- Total equity amounted to 119.9% of total assets at the end of Q4 FY2025, down 453.8 pp from a year earlier.
- Total equity grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +31.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- (24.91M) USD
- Year-over-year change
- +31.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24.91M) | +31.8% |
| FY2024 | 2024-12-31 | (36.52M) | -7.2% |
| FY2023 | 2023-12-31 | (34.07M) | -15.0% |
| FY2022 | 2022-12-31 | (29.63M) | -27.0% |
| FY2021 | 2021-12-31 | (23.33M) | — |
Total Equity vs competitors
How MENS compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +31.8% is the 5th highest of 11, against a peer median of +26.0%.
- Total equity amounts to 119.9% of total assets for MENS, versus a peer median of 73.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.34B CNY | +387.0% | +48.4% | 33.7% |
| Sep 2026 | $1.27B USD | +25.9% | +10.4% | 75.7% | |
| Jun 2026 | $1.19B USD | +92.9% | +85.3% | 89.4% | |
| Sep 2026 | $1.15B USD | +104.9% | -6.9% | 95.5% | |
| Sep 2026 | $990.97M USD | +44.1% | +81.8% | 94.7% | |
| Jun 2026 | $702.15M USD | +22.9% | +56.8% | 70.6% | |
| Mar 2026 | $487.35M USD | +26.2% | +16.2% | 75.9% | |
| Sep 2026 | $22.58M USD | -69.3% | +38.9% | 2.7% | |
| Jun 2026 | -$12.78M USD | -128.8% | -9.1% | 1.5% | |
| Dec 2025 | -$24.91M USD | +31.8% | — | 119.9% | |
| Mar 2026 | -$229M USD | -251.4% | — | 17.7% | |
| Peer median (excluding MENS) | — | +26.0% | +38.9% | 73.2% | |
Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 551K | 718K | 177K | 98K | 1.18M |
| Short-term Investments | 1.83M | 94K | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 13.51M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 263K | 1.65M | 1.66M | 108K | 854K |
| Total Current Assets | 2.65M | 2.46M | 1.84M | 206K | 15.54M |
| Property, Plant & Equipment (Net) | 6.78M | 6M | 3.54M | 3.19M | 5.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8K | 283K | 2.87M | 2.97M | 6K |
| Total Non-current Assets | 6.78M | 6.28M | 6.41M | 6.16M | 5.24M |
| Total Assets | 9.43M | 8.75M | 8.25M | 6.37M | 20.78M |
| Account Payables | 46K | 4K | 2K | 3K | 2K |
| Short-term Debt | 4.93M | 7.65M | 7.97M | 7.28M | 8.36M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 23K | 4.22M | 4.99M | 3.33M | 26.31M |
| Total Current Liabilities | 6.29M | 12.91M | 14.26M | 12.13M | 34.81M |
| Long-term Debt | 6.26M | 6.32M | 8.52M | 10.68M | 10.16M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 19.86M | 19.04M | 19.47M | 20.06M | 688K |
| Total Non-current Liabilities | 26.46M | 25.47M | 28.06M | 30.76M | 10.87M |
| Total Liabilities | 32.76M | 38.38M | 42.32M | 42.89M | 45.68M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (19.03M) | (25.66M) | (30.06M) | (33.08M) | (37.75M) |
| Accumulated OCI | 266K | 590K | 548K | 1.12M | 682K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (23.33M) | (29.63M) | (34.07M) | (36.52M) | (24.91M) |
| Total Debt | 11.79M | 14.25M | 16.69M | 18.14M | 18.55M |
| Net Debt | 11.24M | 13.53M | 16.51M | 18.04M | 17.37M |
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.